Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes

BACKGROUND: The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidney and cardiovascular outcomes in patients with chronic kidney dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Gerasimos, Anker, Stefan D., Agarwal, Rajiv, Pitt, Bertram, Ruilope, Luis M., Rossing, Peter, Kolkhof, Peter, Schloemer, Patrick, Tornus, Ingo, Joseph, Amer, Bakris, George L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864612/
https://www.ncbi.nlm.nih.gov/pubmed/33198491
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864612/
https://www.ncbi.nlm.nih.gov/pubmed/33198491
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051898

Ejemplares similares